Eli Lilly and Company

Patent Owner

Follow Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology MATTERS Rank in Class
 
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 497 22
 
 
C07D HETEROCYCLIC COMPOUNDS 311 17
 
 
C07K PEPTIDES 106 36
 
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 61 38
 
 
A61M DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY 58 81
 
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 45 112
 
 
C07C ACYCLIC OR CARBOCYCLIC COMPOUNDS 37 91
 
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 36 63
 
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 33 22
 
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 28 67
  • No Technologies to Display

Top Patents (by citation)

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2016/0244,465 SELECTIVE BACE1 INHIBITORS Feb 17, 16 Aug 25, 16 [C07D, C07C]
2016/0235,823 METHODS AND COMPOSITIONS FOR REDUCING THE ENVIRONMENTAL IMPACT OF ANIMAL WASTE Apr 29, 16 Aug 18, 16 [A23K, A61K]
2016/0229,835 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS Oct 03, 14 Aug 11, 16 [C07D, A61K]
2016/0215,011 4--5-(PROPAN-2-YL)-1H-PYRAZOL-3-YL BETA-D GLUCOPYRANOSIDE ACETATE Oct 30, 14 Jul 28, 16 [C07H]
2016/0215,045 VEGFA/Ang2 Compounds Jan 25, 16 Jul 28, 16 [A61K, C07K]
2016/0199,438 GIP AND GLP-1 CO-AGONIST COMPOUNDS Jan 05, 16 Jul 14, 16 [A61K, C07K]
2016/0176,896 ERK INHIBITORS Dec 16, 15 Jun 23, 16 [C07D]
2016/0166,695 RAPID-ACTING INSULIN COMPOSITIONS Dec 09, 15 Jun 16, 16 [A61K]
2016/0137,628 Aurora A Kinase Inhibitor Nov 06, 15 May 19, 16 [C07D]
2016/0122,429 ANTI-TNF- / ANTI-IL-23 BISPECIFIC ANTIBODIES Nov 03, 15 May 05, 16 [C07K]

View all publication…

  • No Publications to Display

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9,422,353 Fibroblast growth factor 21 variant, composition , and uses thereof Jun 05, 13 Aug 23, 16 [A61K, C07K]
9,416,138 Benzyl sulfonamide compounds useful as MoGAT-2 inhibitors Oct 30, 13 Aug 16, 16 [C07D]
9,416,182 Anti-TNF-anti-IL-17 bispecific antibodies Mar 04, 14 Aug 16, 16 [A61K, C07K]
9,402,838 Phenoxyethyl piperidine compounds Jan 13, 15 Aug 02, 16 [C07D, A61K]
9,402,957 Automatic injection device with delay mechanism including dual functioning biasing member Apr 25, 14 Aug 02, 16 [A61M]
9,394,317 Imidazo pyridine compounds Mar 04, 14 Jul 19, 16 [C07D, A61K]
9,394,362 IL-21 antibodies and methods of making or using the antibodies Mar 13, 15 Jul 19, 16 [A61K, C07K]
9,376,491 IL-17 antibody formulation and method of treatment using same Mar 01, 13 Jun 28, 16 [A61K, C07K]
9,371,289 Phenoxyethyl dihydro-1H-isoquinoline compounds May 09, 14 Jun 21, 16 [C07D, A61K]
9,371,335 Spirothienopyran-piperidine derivatives as ORL-1 receptor antagonists for their use in the treatment of alcohol dependence and abuse Nov 29, 12 Jun 21, 16 [C07D, A61K]

View all Patent…

  • No Patents to Display

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2015/0376,178 Pyridinoylpiperidines As 5-HT1F Agonists ABAN Jun 05, 14 Dec 31, 15 [C07D]
2015/0203,471 METHODS FOR IMPROVING CHICKEN PRODUCTION ABAN Sep 24, 13 Jul 23, 15 [C07D, C07C, A23K]
2015/0152,158 METHODS TO RESTORE GLYCEMIC CONTROL ABAN Feb 10, 15 Jun 04, 15 [C07K]
2014/0271,671 RANDOM HOMOZYGOUS GENE PERTURBATION (RHGP) WITH THERMAL ASSYMETRIC INTERLACED (TAIL)-PCR ABAN Mar 14, 13 Sep 18, 14 [C12Q]
2014/0275,049 SUBSTITUTED PYRAZOLE ANALOGS As RAR ANTAGONISTS ABAN Oct 19, 12 Sep 18, 14 [C07D, A61K]
2014/0206,613 METHODS TO RESTORE GLYCEMIC CONTROL ABAN Mar 31, 14 Jul 24, 14 [C07K]
2014/0206,877 NOVEL INTERMEDIATE AND PROCESS USEFUL IN THE PREPARATION OF -(2-CHLOROPHENYL)-METHANONE ABAN Mar 27, 14 Jul 24, 14 [C07D]
2014/0171,497 ANIMAL SUPPLEMENTS AND COMPOSITIONS CONTAINING SOLUABLE MONENSIN AND METHODS THEREFOR ABAN Jul 26, 12 Jun 19, 14 [A23K, A61K]
2014/0163,097 ANIMAL SUPPLEMENTS AND FOOD COMPOSITIONS CONTAINING SOLUBLE MONENSIN COMPOSITION, AND METHODS AND PROCESSES THEREFOR ABAN Jul 26, 12 Jun 12, 14 [A23K, A61K]
2014/0056,893 Homodimeric Proteins ABAN Aug 15, 13 Feb 27, 14 [C07K]
2014/0050,763 MODIFIED VIRAL PARTICLES WITH IMMUNOGENIC PROPERTIES AND REDUCED LIPID CONTENT USEFUL FOR TREATING AND PREVENTING INFECTIOUS DISEASES ABAN Oct 30, 13 Feb 20, 14 [A61K]
2014/0024,586 USE OF AN FGF-21 COMPOUND AND A GLP-1 COMPOUND FOR THE TREATMENT OF OBESITY ABAN Oct 03, 13 Jan 23, 14 [A61K]
2013/0228,136 LIQUID DISPENSER ABAN Apr 17, 13 Sep 05, 13 [A01K]
2013/0023,471 METHODS TO RESTORE GLYCEMIC CONTROL ABAN Sep 14, 12 Jan 24, 13 [A61P, A61K]
2012/0323,001 BACE INHIBITORS ABAN Aug 16, 12 Dec 20, 12 [C07D]
2012/0302,547 NOVEL MCH RECEPTOR ANTAGONISTS ABAN Aug 08, 12 Nov 29, 12 [C07D, A61P, A61K]
2012/0294,855 GLP-1 RECEPTOR AGONIST COMPOUNDS FOR OBSTRUCTIVE SLEEP APNEA ABAN Oct 28, 10 Nov 22, 12 [A61P, A61K]
2012/0231,022 GLP-1 RECEPTOR AGONIST COMPOUNDS FOR SLEEP ENHANCEMENT ABAN May 27, 10 Sep 13, 12 [A61P, A61K]
2012/0195,904 METHOD TO TREAT USING ANTAGONISTIC ANTI-hTNFSF13B HUMAN ANTIBODIES ABAN Apr 11, 12 Aug 02, 12 [A61P, A61K]
2012/0172,422 Methods of Treatment Using a Prodrug of an Excitatory Amino Acid ABAN Mar 13, 12 Jul 05, 12 [A61P, A61K]

View all Patent…

  • No Patents to Display

Top Inventors for This Owner

We are sorry but your current selection exceeds the maximum number of follows () for this membership level. Upgrade to our Level for up to follows!

Owner Follow
Eli Lilly and Company
CANCEL
UPGRADE MEMBERSHIP CANCEL

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to comparisons!

UPGRADE MEMBERSHIP CANCEL

We are sorry but your current selection exceeds the maximum number of portfolios () for this membership level. Upgrade to our Level for up to portfolios!

UPGRADE MEMBERSHIP CANCEL

We are sorry but your current selection exceeds the maximum number of patents allowed in portfolios () for this membership level. Upgrade to our Level for up to patents!

UPGRADE MEMBERSHIP CANCEL